Saturday, 23 September 2017
Latest news
Main » Are Analysts Predicting a Near-Term Upswing For Biogen Idec Inc. (NASDAQ:BIIB)?

Are Analysts Predicting a Near-Term Upswing For Biogen Idec Inc. (NASDAQ:BIIB)?

31 January 2017

On the company's financial health, Biogen Inc reported $5.04 EPS for the quarter, beating the analyst consensus estimate by $ 0.08 according to the earnings call on Jan 26, 2017. Risks to achieving Target Price / Valuation: Regeneron Pharmaceuticals - REGN Regeneron's revenues and/or EPS may fall below our estimates, resulting in downside to our target price. Most recently, in October 2015, Alexander Denner, a Director at BIIB bought 310,000 shares for a total of $86,015,000.

12/16/2016 - Cantor Fitzgerald began new coverage on Biogen Idec Inc. giving the company a " rating.

Currently, the analyst consensus on Biogen Inc is Moderate Buy and the average price target is $338.67, representing a 21.7% upside. Biogen presently has an average rating of "Buy" and an average price target of $332.75. The Hedge Fund company now holds 2,644 shares of BIIB which is valued at $723,980.

01/17/2017 - Biogen Idec Inc. had its " rating reiterated by analysts at BMO Capital Markets. The mean consensus price target now stands at $333.142.

Boasting a price of $276.06, Biogen Inc (NASDAQ:BIIB) traded -0.77% lower on the day. Northern Trust Corp now owns 2,978,479 shares of the biotechnology company's stock worth $932,354,000 after buying an additional 12,483 shares during the last quarter. Biogen has a 52 week low of $223.02 and a 52 week high of $333.65.

The stock's 50 day moving average is 285.37 and its 200 day moving average is 297.82. The stock's market capitalization is 59.79B. Biogen Inc makes up approx 0.10% of Raymond James Trust N.a.'s portfolio.Hills Bank Trust Co boosted its stake in BIIB in the latest quarter, The investment management firm added 254 additional shares and now holds a total of 4,564 shares of Biogen Inc which is valued at $1,291,658. Biogen had a return on equity of 40.02% and a net margin of 34.03%. The firm earned $2.96 billion during the quarter, compared to the consensus estimate of $2.91 billion. During the same quarter in the previous year, the company posted $4.50 EPS. The firm's quarterly revenue was up 1.2% on a year-over-year basis.

Based on the latest notes released to investors, 8 analysts have issued a rating of "buy", 8 analysts "outperform", 9 analysts "hold", 0 analysts "underperform" and 0 analysts "sell". Baystate Wealth Management LLC now owns 1,019 shares of the biotechnology company's stock valued at $319,000 after buying an additional 5 shares during the last quarter. Norway Savings Bank purchased a new stake in Biogen during the fourth quarter valued at $484,000. It would take about 1.24 days to cover all short positions. Buckingham Asset Management LLC now owns 865 shares of the biotechnology company's stock valued at $209,000 after buying an additional 15 shares during the last quarter. Finally, Woodstock Corp increased its position in Biogen by 0.6% in the third quarter. The company's shares closed last Friday at $278.21. The correct version of this article can be read at The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment.